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Many cancer cells follow an aberrant metabolic program to maintain energy for rapid cell proliferation.
Metabolic reprogramming often involves the upregulation of glutaminolysis to generate reducing
equivalents for the electron transport chain and amino acids for protein synthesis. Critical enzymes in-
volved in metabolism possess a reactive thiolate group, which can be modiﬁed by certain oxidants. In the
current study, we show that modiﬁcation of mitochondrial protein thiols by a model compound, iodo-
butyl triphenylphosphonium (IBTP), decreased mitochondrial metabolism and ATP in MDA-MB 231
(MB231) breast adenocarcinoma cells up to 6 days after an initial 24 h treatment. Mitochondrial thiol
modiﬁcation also depressed oxygen consumption rates (OCR) in a dose-dependent manner to a greater
extent than a non-thiol modifying analog, suggesting that thiol reactivity is an important factor in the
inhibition of cancer cell metabolism. In non-tumorigenic MCF-10A cells, IBTP also decreased OCR;
however the extracellular acidiﬁcation rate was signiﬁcantly increased at all but the highest con-
centration (10 mM) of IBTP indicating that thiol modiﬁcation can have signiﬁcantly different effects on
bioenergetics in tumorigenic versus non-tumorigenic cells. ATP and other adenonucleotide levels were
also decreased by thiol modiﬁcation up to 6 days post-treatment, indicating a decreased overall energetic
state in MB231 cells. Cellular proliferation of MB231 cells was also inhibited up to 6 days post-treatment
with little change to cell viability. Targeted metabolomic analyses revealed that thiol modiﬁcation caused
depletion of both Krebs cycle and glutaminolysis intermediates. Further experiments revealed that the
activity of the Krebs cycle enzyme, aconitase, was attenuated in response to thiol modiﬁcation. Ad-
ditionally, the inhibition of glutaminolysis corresponded to decreased glutaminase C (GAC) protein levels,
although other protein levels were unaffected. This study demonstrates for the ﬁrst time that mi-
tochondrial thiol modiﬁcation inhibits metabolism via inhibition of both aconitase and GAC in a breast
cancer cell model.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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One of the hallmarks of cancer cell transformation is the dys-
regulation of energetic pathways [1]. This process, known as
“metabolic reprogramming,” involves an increased reliance on
glycolysis independent of oxygen levels to not only provide ATP,
but also to provide intermediates for new lipids, amino and nucleic
acids needed for rapid cell proliferation. In addition, upregulation
of glutaminolysis is observed in many diverse cancer types in-
cluding breast cancer, glioblastoma multiforme, and pancreatic
cancer [2–7]. Glutaminolysis is an anaplerotic pathway that re-
plenishes the Krebs cycle by the conversion of glutamine to α-
ketoglutarate, thereby providing reducing equivalents to drive
electron transport. Glutaminolysis is also important in providing
intermediates necessary for the rapid synthesis of amino acids and
glutathione [8,9]. In cancer cells, upregulation of glutaminolysis
within the mitochondrion allows for generation of ATP with high
efﬁciency, while also generating substrates required in protein
synthesis serving as a complement to glycolysis for biomass
synthesis and energy production [7].
Cells that are dependent on glutamine for proliferation are
termed “glutamine addicted,” and this feature presents an at-
tractive therapeutic target, due to the fact that most normal non-
tumorigenic cells are not glutamine addicted [10]. A key mediator
of glutamine-addiction, the enzyme glutaminase C (GAC), is up-
regulated as a result of oncogenic gene transcription, and has re-
cently become a widely-recognized target for the development of
novel therapeutics [11–13]. However, current GAC inhibitors suffer
from relatively low solubility, low-afﬁnity and high toxicity [14–
16], making novel inhibitors of glutaminolysis attractive for de-
velopment. Of note, recent studies have also indicated that GAC
possesses a reactive cysteine thiolate, which have been char-
acterized as redox switches for other proteins involved in path-
ways such as metabolism and cellular proliferation [17,18].
In order to inhibit metabolism within the mitochondrion, it is
necessary to design agents which not only enter the organelle, but
an also inhibit one or more enzymes within the pathway. An ef-
fective method to target compounds to the mitochondrion is by
coupling to a lipophilic cationic moiety, such as triphenylpho-
sphonium (TPP), which allows the conjugated product to accu-
mulate within the mitochondrion 100–500 fold based on mi-
tochondrial membrane potential [19,20]. TPP has been used to
target compounds such as doxorubicin, coenzyme Q, and electro-
philes to the mitochondria to enhance cell death, protect against
oxidative stress, or modulate antioxidant responses, respectively
[21–23]. Iodobutyl triphenylphosphonium (IBTP) is a mitochon-
dria-targeted electrophile which was originally developed as a
research tool to probe the status of reduced thiols in isolated mi-
tochondria, cell culture models, and isolated tissues from animal
models of oxidative stress [24,25]. In a previous study, we reported
that IBTP affected cellular function by inhibiting Nrf2-dependent
antioxidant responses in endothelial cells [26]. More recently, we
showed that IBTP inhibited overall metabolism in breast cancer
cells after a short (4h) exposure, and also prevented cell migration
and adhesion [27]. Due to the soft electrophilic nature of IBTP, this
compound forms a covalent adduct with speciﬁc cysteinyl thiol
groups of proteins, many of which play a central role in cell me-
tabolism [24,25,28,29].
In this study, we sought to determine the mechanisms by
which mitochondrial thiol modiﬁcation inhibits metabolism in
MDA-MB-231 (MB231) cells. MB231 cells represent a prototype of
metabolically reprogrammed glutamine-dependent cancer cells.
These “triple-negative” cells are characterized by lacking estrogen,
progesterone, and Her2/neu receptors. In addition, these cells are
rapidly proliferating, tumorigenic and metastatic, making them an
ideal model for aggressive cancer cell types. Herein, we show thatmitochondrial thiol modiﬁcation blocks energy production by
decreasing protein levels and activity, depleting Krebs cycle in-
termediates and inhibiting oxidative phosphorylation, ultimately
decreasing ATP levels. Furthermore, our data suggest that likely
mechanisms of IBTP inhibition of metabolism include decreasing
enzyme activity and/or decreasing protein levels.2. Experimental
2.1. Materials
All chemicals were of analytical grade and purchased from
Sigma-Aldrich (St. Louis, MO) unless otherwise noted. IBTP and
BTPP were prepared as previously described [24]. Anti-TPP anti-
serum was prepared as previously described [24]. Monoclonal
[Abcam (Cambridge, MA), ab156876] or polyclonal [Proteintech
(Chicago, IL), 23549-1-AP] anti-glutaminase antibodies were used
as indicated in the. Other antibodies used were anti-β-actin [Cell
Signaling (Beverly, MA], polyclonal anti-citrate synthetase [Abcam,
ab96600], anti-complex IV subunit 2 [Life Technologies (Grand
Island, NY); 20E8C12], afﬁnity puriﬁed anti-aconitase (a generous
gift from Dr. Scott Ballinger at UAB, prepared as described in [30]).
The anti-aconitase antibody recognizes both mitochondrial and
cytosolic aconitase (ACO2 and ACO1, respectively) isoforms in
human breast cancer cells at distinguishable molecular weights
(unpublished observations Smith, Zhou, Landar).
2.2. Cell culture and treatments
MDA-MB-231 (MB231) human breast adenocarcinoma cells
were a generous gift from Dr. Danny Welch, and were originally
obtained from ATCC (Manassas, VA). MB231 were cultured in
Dulbecco's modiﬁed Eagle's medium/F12 (DMEM/F12) (Mediatech,
Manassas, VA) supplemented with 10% fetal bovine serum (FBS;
Atlanta Biologicals, Atlanta, GA). Cultures were maintained in 5%
CO2 and humidiﬁed in a 37 °C incubator. Cells were plated at a
density of 2105 cells/well in 6-well plates and cultured for 48 h,
unless otherwise indicated. The medium was changed to low FBS
medium (0.5%) for 16 h prior to treatments. Cells were treated
with EtOH vehicle, IBTP or BTPP in 2 mL of fresh medium at con-
centrations and times indicated in each experiment. MCF-10A
human breast epithelial cells were a generous gift from Dr. Danny
Welch, and were originally obtained from ATCC (Manassas, VA).
MCF10Awere cultured in Dulbecco's modiﬁed Eagle's medium/F12
(DMEM/F12) (Mediatech, Manassas, VA) supplemented with Bul-
letKit™ (Lonza; Basel Switzerland). Cultures were maintained in
5% CO2 and humidiﬁed in a 37 °C incubator. Cells were plated at a
density of 2105 cells/well in 6-well plates and cultured for 48h,
unless otherwise indicated. The medium was changed to low
supplement medium (0.5%) for 16h prior to treatments. Cells were
treated with EtOH vehicle, IBTP or BTPP in 2 mL of fresh medium
at concentrations and times indicated in each experiment.
2.3. Immunoblot analysis
Cells were washed with PBS and lysed in Lysis Buffer [10 mM
Tris–HCl, pH 7.4, 1% Triton X-100 containing protease inhibitor
cocktail (PIC; Roche)]. Soluble proteins were resolved using SDS-
PAGE and transferred to nitrocellulose membranes (Bio-Rad).
Protein levels were quantiﬁed using the method of DC-Lowry (Bio-
Rad), and equivalent amounts of protein were loaded. Uniform
protein loading was conﬁrmed using Ponceau S staining of
membranes and showed no signiﬁcant differences in protein levels
among samples. Membranes were blocked in 5% milk (w/v) in Tris
Buffered Saline (pH 7.4) containing 0.05% Tween 20 (TBS-T), and
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(1:10,000), monoclonal anti-GAC/KGA/GAM (1:3000), anti-citrate
synthase (1:1000), anti-complex IV subunit 2 (1:1000), anti-β-ac-
tin (1:1000), anti-aconitase 1 (1:5000), and anti-TPP (1:10,000)
primary antisera]. All antibodies were incubated overnight at 4 °C,
except anti-TPP which was incubated for 3h at ambient tempera-
ture. Membranes were washed, incubated with HRP-conjugated
anti-rabbit or anti-mouse IgG secondary antibody, and developed
using SuperSignal West Dura chemiluminescence substrate
(Pierce). Images were obtained using an Amersham™ Imager 600
(GE Healthcare Biosciences; Pittsburg PA).
2.4. Metabolic rate assessment
To measure mitochondrial metabolism in intact MB231 cells, an
XF96 Extracellular Flux Analyzer was used with a mitochondrial
“stress test” [32]. The optimal seeding density of MB231 was de-
termined to be 15,000 cells per well and MCF10Awere determined
to be 40,000 cells per well. The mitochondrial stress test was
performed as described previously [33–35]. Concentrations of
oligomycin, carbonyl cyanide p-triﬂuoromethoxyphenylhydrazone
(FCCP), and antimycin A were optimized prior to the assay for each
cell line. In our calculations, the oligomycin-insensitive oxygen
consumption rate (OCR) was attributed to proton leak. To de-
termine the effects of IBTP at a later time point on mitochondrial
metabolism, cells were cultured as previously described. The cells
were treated with the indicated concentrations of IBTP or BTPP for
24 h in 0.5% FBS-containing or 0.5% nutrient-containing medium.
After the incubation, the cells were harvested immediately by
trypsinization and replated at a density of 15,000 or 40,000 cells
per well into XF96 plates for an additional 24 h in complete
medium containing 10% FBS or 10% nutrients (total 48 h). After
incubation, the medium was removed and replaced with XF assay
medium (DMEM, containing 15 mM glucose, 2.5 mM glutamine,
0.5 mM pyruvate without bicarbonate) and equilibrated 1h before
OCR measurement. Both OCR and extracellular acidiﬁcation rate
(ECAR) measurements were normalized to number of cells plated
per well (15,000 or 40,000 cells respectively) because total protein
per well was below limit of detection for the MB231 cells.
2.5. Targeted metabolomic analysis
Cells were cultured as described above and treated with ve-
hicle, IBTP (10 mM) or BTPP (10 mM), for 24 h. Cells were then
washed with PBS and lysed with 500 mL of ﬁltered HPLC grade
methanol. The wells were scraped and 2 wells pooled and col-
lected for sample analysis in a glass tube. The methanol extracts
were brought to the Targeted Metabolomics and Proteomics La-
boratory where they were stored at 80° until analyzed. The
samples were taken to dryness under a stream of nitrogen gas.
Samples were reconstituted by the addition of 50 mL of 5% acetic
acid followed by vortex mixing. 50 mL of Amplifex Keto Reagent Kit
(Applied Biosystems part number 4465962) was then added to
each sample with vortex mixing. Tubes were capped and placed
on a rotary shaker. After 90 min, samples were removed, vortexed
a ﬁnal time, and placed under a stream of nitrogen gas until dry.
Final reconstitution was in 500 mL Milli-Q water. Separation of the
Krebs Cycle metabolites was performed on a Synergi 4m Hydro-RP
80A column (Phenomenex part number 00G-4375-B0) with di-
mensions of 2.0250 mm. Mobile phase A was waterþ0.1% for-
mic acid, mobile phase B was methanolþ0.1% formic acid. Flow
rate was 0.25 mL/min with the following gradient: 0 min¼5% B,
1 min¼5% B, 7 min¼40% B, 10 min¼100% B, 10.5 min¼5% B,
15 min¼stop. Injection volume was 10 mL.2.6. Nucleotide extraction
All nucleotide samples were prepared by modifying a method
previously described [31]. Brieﬂy, an aliquot of protein-pre-
cipitated lysate was obtained from MB231 cells after the indicated
treatments by scraping the cells after addition of 5% perchloric
acid. The lysate was centrifuged (20,800g for 5 min at 4 °C) and the
supernatant was transferred into an Eppendorf tube and neu-
tralized by precipitating ClO4 with K2HPO4. The suspension was
vortexed, kept on ice for 10 min and then centrifuged (as above) to
remove salt. The supernatant was used immediately or stored at
80 °C until analysis. The precipitated protein pellet was stored
and later resuspended in 300 mL of 1N NaOH and protein con-
centration was determined by DC-Lowry with BSA as a standard.
2.7. HPLC separation and measurement of adenine nucleotides
Nucleotide analysis was performed as previously described
[31]. The HPLC consisted of a Gold HPLC model equipped with
System Gold 168 Detector and System Gold Autosampler 507 from
Beckman Coulter. The analytical column was a Supelcosil LC-18-T,
(150 mm4.6 mm internal diameter, particle size 3 mm) from
Sigma-Aldrich. Analytical runs were processed by 32 Karat Soft-
ware (version 8.0) also from Beckman Coulter. The chromato-
graphic separation was performed at ambient temperature with
gradient elution. The mobile-phase ﬂow rate was set at 1 ml/min
and consisted of 65 mM potassium phosphate buffer and 4 mM
tetrabutylammonium hydrogen sulfate (TBAHS) adjusted to pH
6.0 with orthophosphoric acid (Buffer A) and 30% MeOH in 65 mM
potassium phosphate buffer with 4 mM TBAHS adjusted to pH
6.0 with orthophosphoric acid (Buffer B). The buffers were deliv-
ered in a gradient as follows: 0–2 min, 30% Buffer B, 2–16 min to
90% Buffer B; 16–20 min to 90% Buffer B; 20–21 min returned to
30% Buffer B; and 21–24 min 30% Buffer B using an 2 min equili-
bration between injections. The injection volume was 10 mL. Nu-
cleotides were monitored at 254 and 262 nm. Standard AMP, ADP,
ATP and NADþ were dissolved in Buffer A at concentrations from
2 to 100 mM to create a standard curve. Standards were not ﬁltered
prior to injection. Experimental samples were prepared as follows:
a volume of 150 mL of nucleotide extract suspension was mixed 1:1
with 150 mL of Buffer A and ﬁltered prior to injection in HPLC.
2.8. ATP luminescence assay
Relative ATP levels were determined using the luminescence
based ATPLite™ assay (Perkin-Elmer, Waltham, MA) and measured
on a TopCount NXT microplate scintillation and luminescence
counter (Packard, Meriden, CT). In brief, cells were cultured as
described above. The cells were then treated with IBTP (0.01–
10 mM), BTPP (0.01–10 mM) or vehicle (EtOH) for 24 h, and media
replaced with 10% FBS DMEM/F12 for an additional 24 h, to allow
cells to recover. For experiments exceeding 24 h, cells were treated
as described above, and media was replaced every 48 h with 10%
FBS DMEM/F12 until day 6. To measure ATP, 1.5 mL media was
decanted and 250 mL of the ATPLite™ Lysis Buffer was added to the
remaining 0.5 mL media in each well. Samples were mixed on an
orbital shaker for 5min, samples were dark-adapted, and lumi-
nescence was measured. In order to determine protein con-
centration, a parallel well was lysed in 80 mL of lysis buffer as
described above, and protein measured by DC Lowry.
2.9. Aconitase activity assay
The method was performed as previously described [32,33]. In
brief, cells were cultured as described above. The cells were then
treated with IBTP (5–10 mM), BTPP (5–10 mM), or vehicle (EtOH) for
Fig. 1. Mitochondrial stress test dose response curves. MB231 cells were treated with vehicle (EtOH), IBTP (0.01–10 mM), or BTPP (0.01–10 mM) for 24 h and a mitochondrial
stress test was performed as described in the Methods. Panel A: Dose response of IBTP or BTPP on basal respiration. Panel B: Dose response of IBTP or BTPP on maximal
respiration. C: Dose response of IBTP or BTPP on ADP-dependent respiration D: Dose response of IBTP or BTPP on non-mitochondrial respiration. E: Dose Response of IBTP or
BTPP on proton leak F: Dose response of IBTP or BTPP on reserve capacity. Values are mean7SEM obtained from 11 to 24 wells in three separate experiments; *Po0.05
compared to vehicle; # Po0.05 compared to BTPP.
M.R. Smith et al. / Redox Biology 8 (2016) 136–148 13924 h. The cells were then washed with PBS and lysed with Lysis
buffer [50 mM Tris, pH 7.4, 0.6 mM MnCl2 2 mM sodium citrate,
and 0.5% Triton X100]. 50 mg of protein was loaded onto a native
gel [8% acrylamide, 132 mM Tris, 132 mM borate, 3.5 mM citrate]
and a stacker [4% acrylamide, 67 mM Tris base, 67 mM borate,3.6 mM citrate]. The running buffer contains 25 mM Tris, pH 8,
192 mM glycine, 3.6 mM citrate. Samples contain cell lysates,
25 mM Tris-Cl, pH 8, 0.025% sodium bromophenol blue, 10% gly-
cerol. Electrophoresis was carried out at 180 V at 4 °C for 3 h. The
gels were then incubated with staining solution [100 mM Tris, pH
Fig. 2. Mitochondrial stress test dose response curves. MCF-10A cells were treated with vehicle (EtOH), IBTP (0.0–10 mM), or BTPP (0.01–10 mM) for 24 h and a mitochondrial
stress test was performed as described in the Methods. Panel A: Dose response of IBTP or BTPP on basal respiration. Panel B: Dose response of IBTP or BTPP on maximal
respiration. C: Dose response of IBTP or BTPP on ADP-dependent respiration D: Dose response of IBTP or BTPP on non-mitochondrial respiration. E: Dose Response of IBTP or
BTPP on proton leak F: Dose response of IBTP or BTPP on reserve capacity. Values are mean 7SEM obtained from 13 to 26 wells in three separate experiments; *Po0.05
compared to vehicle; # Po0.05 compared to BTPP.
M.R. Smith et al. / Redox Biology 8 (2016) 136–1481408, 1 mM NADPþ , 2.5 mM cis-aconitic acid, 5 mM MgCl2, 1.2 mM
MTT, 0.3 mM phenazine methosulfate, and 5 U/mL isocitrate de-
hydrogenase (Sigma #i2002) for 30 min in the dark at 37 °C. Thereaction was then stopped by 2 washes of 100 mM Tris, pH 8.
Images were then taken using an Amersham™ Imager 600 (GE
Healthcare Biosciences; Pittsburg PA)
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Cell survival was determined by trypan blue exclusion. Brieﬂy,
cells were seeded at 200,000 cells/well in a 6 well plate and in-
cubated at 37° for 48 h in DMEM/F12 10% FBS. The cells were then
transferred to 2 mL 0.5% FBS DMEM/F12 media overnight. The cells
were then treated 10 mM IBTP, 10 mM BTPP or Vehicle (EtOH) for
24 h. The media was then replaced with 10% FBS DMEM/F12 and
was replaced every 48 h until day 6. At each of the indicated time
points cells were trypsinized using 0.5 mL of 0.05% Trypsin EDTA,
and neutralized via 0.5 mL of 10% FBS DMEM/F12 media. Cells
were then counted via a Biorad TC20™ automated cell counter and
cell survival was determined using Trypan Blue Due 0.4% (Bio-rad,
Hercules, CA).
2.11. Cell Proliferation Assessment
Cell proliferation was determined by counting the cells using a
hemocytometer. Brieﬂy, cells were seeded at 200,000 cells/well in
a 6 well plate and incubated at 37° for 48 h in DMEM/F12 10% FBS.
The cells were then transferred to 2 mL 0.5% FBS DMEM/F12 media
overnight. The cells were then treated 10 mM IBTP, 10 mM BTPP or
Vehicle (EtOH) for 24 h. The media was then replaced with 10%
FBS DMEM/F12 and was replaced every 48 h until day 6. At each of
the indicated time points cells were trypsinized using 0.5 mL of
0.05% Trypsin EDTA, and neutralized via 0.5 mL of 10% FBS DMEM/
F12 media. Cells were then counted via a Biorad TC20™ automated
cell counter (Bio-rad, Hercules, CA)
2.12. Statistical analysis
Results are reported as mean7SEM, and n¼3 or more de-
terminations, or otherwise as indicated in the. Data were analyzed
by unpaired t-tests or one-way analysis of variance (ANOVA) fol-
lowed by Tukey post-hoc analysis using GraphPad Software. The
minimum level of signiﬁcance was set at po0.05.Fig. 3. XF Metabolic Phenogram. Panel A: Basal OCR and ECAR rates were plotted in
response to a 24h treatment of vehicle (EtOH; ), IBTP (0.01 mM; , 0.05 mM; ,
0.1 mM; , 0.5 mM; , 1 mM; , 2.5 mM; , and 10 mM; ) or BTPP (0.01 mM;
, 0.05 mM; , 0.1 mM; , 0.5 mM; , 1 mM; , 2.5 mM; , and 10 mM; ) in
MB231 cells. Panel B: Basal OCR and ECAR were plotted plotted in response to a
24 h treatment of in MCF-10A cells using the concentrations and values from above.
Values are mean7SEM obtained from 11 to 26 wells in 3 separate experiments.3. Results
3.1. Mitochondrial thiol modiﬁcation affects bioenergetics
IBTP forms covalent mitochondrial protein adducts, and at
concentrations of 5 or 10 mM for 4 h, inhibits bioenergetics in
MB231 cells [27]. However, the effects of lower doses of IBTP for
longer treatment times on bioenergetics have not been fully ex-
plored in these cells. Therefore, extracellular ﬂux analysis was
used to measure glycolytic and mitochondrial bioenergetic para-
meters. MB231 cells were treated for 24 h with a dose range (0.01–
10 mM) of IBTP, a non-electrophilic compound BTPP, or vehicle
(EtOH). Bioenergetic parameters were measured using a mi-
tochondrial stress test, and changes in the oxygen consumption
rates are shown in Fig. 1. Mitochondrial thiol modiﬁcation by IBTP
was found to decrease basal, ATP-dependent respiration, maximal,
and non-mitochondrial respiration bioenergetic parameters, ex-
cluding reserve capacity and proton leak, from 0.5 mM to 10 mM
compared to vehicle (indicated as 0 mM) and also exhibited dif-
ferential effects from BTPP (Fig. 1A–D). BTPP also decreased basal,
non-mitochondrial respiration, ATP-dependent respiration, max-
imal respiration, and proton leak excluding reserve capacity, but at
higher concentrations than those seen with IBTP, (1–10 mM);
however BTPP also exhibited unique changes proton leak when
compared to IBTP (0.1 mM).
In order to determine whether IBTP elicited these effects in a
non-cancer cell line, we utilized the immortalized epithelial cell
line MCF-10A utilizing the same dose range of BTPP and IBTP fromabove (0.01–10 mM) and the results are shown in Fig. 2. Mi-
tochondrial thiol modiﬁcation was also found to also decrease
basal respiration, maximal respiration, ATP-dependent respiration,
non-mitochondrial respiration, proton leak, and reserve capacity
in MCF-10A cells at concentrations form 0.1 mM and above com-
pared to vehicle (also indicated as 0 mM) and also exhibited dif-
ferential effects from BTPP (Fig. 2A–F) Interestingly at lower con-
centrations IBTP increased proton leak at 0.05 and 0.1 mM con-
centrations then subsequently dedcreased again. BTPP also ex-
hibited signiﬁcant decreases in all of the above parameters at the
highest concentrations (2.5 and 10 mM) while also exhibiting sig-
niﬁcant increases in basal respiration, maximal respiration proton
leak, and reserve capacity at concentrations 0.01–2.5 mM. These
results indicate the ability of IBTP to signiﬁcantly alter bioener-
getics is due to a complex integration between its ability to modify
particular protein thiolates and the effects on mitochondrial
function of its targeting moiety in both tumorigenic and non-tu-
morigenic cells.
In order to determine how mitochondrial modiﬁcation by IBTP
shifts overall cellular metabolism as concentrations increase, basal
OCR which is indicative of OXPHOS was then plotted as a function
of basal ECAR (Fig. S1), which is assumed to be representative of
glycolytic function to form a bioenergetic phenogram in to de-
termine the overall metabolic phenotype of the cells (Fig. 3). In
Fig. 4. ATP measurements by ATPLite™. Cells were plated on 6-well plates and
treated with vehicle (EtOH), IBTP (0.01–10 mM), or BTPP (0.01–10 mM) for 24 h in
0.5% FBS-containing medium. After incubation, medium was changed to 10% FBS-
containing medium. Cells were lysed and ATP values were expressed as percent
vehicle at each time point Panel A: ATP measurements day 1 post-treatment Panel
B: ATP measurements day 6 post-treatment. Values are mean7SEM obtained from
2 separate experiments. *Po0.05 compared to vehicle. #Po0.05 compared to
BTPP.
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effects on bioenergetics at lower concentrations (0–0.1 mM) after
modiﬁcation of IBTP; however as concentrations of IBTP increased
(0.5–1 mM) a shift from the energetic quadrant to a more glycolytic
state was seen in the MB231 cells indicating a perturbation of
oxidative phosphorylation (OXPHOS). At higher concentrations of
IBTP (2.5–10 mM) the MB231 cells shifted into the quiescent state
indicating perturbations in both OCR and ECAR indicating dis-
ruptions in both OXPHOS and glycolytic paradigms respectively
(Fig. 3A). BTPP also elicited a shift to a glycolytic state at higher
concentrations (1–10 mM) with loss of OCR function, but did not
signiﬁcantly decrease ECAR to the same extent as IBTP (Fig. 3A). In
MCF10A cells, a signiﬁcant decrease in OCR was also seen at
concentrations of 0.5–10 mM IBTP, indicating a similar loss of OX-
PHOS capability in non-tumorigenic cells. However, in contrast to
MB231 cells, IBTP signiﬁcantly increased ECAR at concentrations
from 0.5 to 2.5 mM then lowered basal ECAR to baseline at 10 mM,
indicating that IBTP effects on ECAR are different between these
two cell types. BTPP showed slight inhibitory effects on OCR in
both cell lines which became more pronounced at higher con-
centrations (e.g. 2.5–10 mM); whereas, BTPP caused a compensa-
tory increase in ECAR at these higher concentrations in MCF10A
cells only (Fig. 3B). These results indicate that mitochondrial thiol
modiﬁcation alters the metabolic phenotype in both MB231 and
MCF10A cells, and the ability of these cells to compensate for the
loss of OXPHOS via glycolysis is likely to be dependent on the basal
energetic requirements of the cell type. Additionally, higher en-
ergetic cells, like MB231 appear to shift these to a more quiescent
energetic state after 24 h exposure to IBTP. Overall, these results
suggest that IBTP may have differential metabolic effects according
to cell type.
3.2. Mitochondrial thiol modiﬁcation affects ATP levels
Decreased bioenergetic parameters could result in decreased
ATP levels; therefore, we measured levels of ATP after mitochon-
drial thiol modiﬁcation by IBTP using a luminescence assay. IBTP
caused a decrease at higher concentrations (2.5–10 mM) at day
1 post-treatment compared to either vehicle or BTPP. At day
6 post-treatment, ATP levels remained decreased when compared
to vehicle and BTPP (0.5–10 mM). BTPP exhibited no changes to
ATP at any concentration at either day 1 post-treatment or day
6 post-treatment (Fig. 4A–B).
Because decreased ATP levels could indicate either altered en-
ergetic status or cell death, changes to other key adenonucleotides
in response to mitochondrial thiol modiﬁcation were also analyzed
using an HPLC-based technique. Adenonucleotide levels were
monitored at days 0, 1 and 6 post-treatment, and IBTP decreased
overall ATP to approximately 40% of vehicle control at day 6 post-
treatment (Fig. 5A). NADþ levels were also decreased by IBTP
compared to vehicle or BTPP (Fig. 5B). AMP exhibited no changes
at any time points, whereas ADP levels were decreased by BTPP
and IBTP at day 6 post-treatment (Fig. 5C and D) though the effect
of IBTP was more pronounced. The ATP: ADP ratio indicates cel-
lular energy supply and demand, and these values were higher
with both BTPP and IBTP at day 6 post-treatment (Fig. 5E). When
these data were replotted as % of vehicle control, the relative de-
crease in adenonucleotides over time is more apparent (Fig. S2),
demonstrating that although absolute amounts of adenonucleo-
tides increase over time, the relative levels compared with vehicle
at each time point are actually decreased. These results indicate
that mitochondrial thiol modiﬁcation by IBTP in cancer cells cau-
ses a sustained reduction in both energetic supply and demand in
treated cells. The targeting moiety BTPP also caused a slight de-
crease in ADP and an increase in the ATP: ADP ratio indicating that
the targeting moiety may play a role in decreasing energeticdemand. Despite the remarkable decreases in adenonucleotides,
cell survival was only slightly decreased at day 4, while no changes
to cell survival were observed at day 6 (Fig. 6A). However, overall
cell numbers were signiﬁcantly decreased compared to either ve-
hicle or BTPP (Fig. 6B) indicating that cellular proliferation was at-
tenuated by mitochondrial thiol modiﬁcation. However, signiﬁcant
cell proliferation was observed with BTPP at day 2 and beyond, in
contrast to IBTP. These results indicate that the decrease in en-
ergetic demand caused by the mitochondrial thiol modiﬁcation of
IBTP does not induce apoptosis but rather switches cells into a more
quiescent energetic state and inhibits cellular proliferation.
3.3. Mitochondrial thiol modiﬁcation effects on metabolite levels
In order to determine the effects of mitochondrial thiol mod-
iﬁcation on glycolysis and the Krebs cycle in MB231 cells, key
metabolites were measured in response to IBTP (10 mM) after a
24 h exposure. Mitochondrial thiol modiﬁcation decreased the
glycolytic intermediates glucose-6-phosphate and fructose-6-
phosphate when compared to vehicle and BTPP, while both pyr-
uvate and lactate were unchanged. IBTP also decreased Krebs cycle
metabolites citrate, α-ketoglutarate, succinate, malate and ox-
aloacetate (Fig. 7). Isocitrate and fumarate were below the limit of
detection in cells treated with IBTP. Additionally, IBTP increased
the amino acid glutamine and decreased glutamate, indicating
inhibition of the glutaminolysis pathway. BTPP also decreased ci-
trate, isocitrate, succinate, and glutamine, indicating that the
Fig. 5. Cellular adenine nucleotide levels. Cells were plated on 6-well plates and treated with vehicle (EtOH), IBTP (10 mM), or BTPP (10 mM) for 24 h in 0.5% FBS-containing
medium. After incubation, medium was changed to 10% FBS-containing medium. At days 0, 1, and 6, cells from one 6-well plate were lysed and adenine nucleotides were
measured by HPLC analysis Panel A: ATP levels were expressed as nmol/mg protein. Panel B: NADþ levels were expressed as nmol/mg protein Panel C: AMP levels were
expressed as nmol/mg protein. Panel D: ADP levels were expressed as nmol/mg protein. Panel E: Ratio of ATP to ADP at each time point. Values are mean7SEM obtained
from 3 separate experiments. *Po0.05 compared to vehicle. #Po0.05 compared to BTPP.
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extent than IBTP. These results indicate that mitochondrial thiol
modiﬁcation decreases metabolites within the Krebs cycle and
anaplerotic pathways feeding into the Krebs cycle, including glu-
taminolysis and glycolysis.3.4. Mitochondrial thiol modiﬁcation effects on aconitase
The fact that Krebs cycle metabolites were decreased with
mitochondrial thiol modiﬁcation suggests inhibition of substrate
entry at one or more key regulatory enzymes. Aconitase (ACO) was
Fig. 6. Cell survival and proliferation after mitochondrial thiol modiﬁcation. Panel
A: MB231 cells were treated with vehicle (EtOH), IBTP (10 mM), or BTPP (10 mM) for
24h and cell survival were measured by trypan blue exclusion as described in the
methods. Panel B: Cells were treated as above and overall cellular proliferation was
measured by counting cells using an automated hemocytometer. The values are
mean7SEM, n¼3 samples obtained from 1 independent experiment. *Po0.05 vs
vehicle, #Po0.05 vs BTPP.
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tivity was determined in response to IBTP [25,28]. An in-gel ac-
tivity assay was used to monitor both cytosolic and mitochondrial
aconitase activities in response to EtOH vehicle, BTPP, and IBTP (5
or 10 mM) for 24 h. Mitochondrial aconitase activity was decreased
after treatment with IBTP at both concentrations when compared
to vehicle and BTPP; however cytosolic aconitase was decreased
only at the highest concentration (10 mM) of IBTP (Fig. 8). BTPP
exhibited no effects on either isoform of aconitase at any of the
concentrations used. These results indicate that mitochondrial
thiol modiﬁcation decreases activity of aconitase and that one of
the ﬁrst committed steps in the Krebs cycle is regulated by thiol
status. Abundance of cytosolic aconitase protein was measured by
western blot and no changes in protein level were observed in
response to either IBTP or BTPP; while mitochondrial aconitase
was below the limit of detection (data not shown).
3.5. Mitochondrial thiol modiﬁcation effects on GAC
Glutaminolysis in many cancer cells is mediated by glutaminase
C (GAC), a splice variant of kidney-type glutaminase (KGA) which
is thought to possess a reactive thiol group [17]. As previously
shown in Fig. 6, mitochondrial thiol modiﬁcation increased glu-
tamine levels and decreased glutamate levels indicating inhibition
of the glutaminolysis pathway. Therefore, the effects of the IBTP on
GAC protein levels were monitored. MB231 cells were treated for
24 h with EtOH vehicle, IBTP or BTPP (10 mM), and abundance of
GAC was determined by western blot (Fig. 9). Mitochondrial thiolmodiﬁcation by IBTP decreased GAC protein levels, compared to
vehicle and BTPP, which was found to have had no effect on GAC
levels. Additionally, IBTP had no effect on levels of other mi-
tochondrial and cytosolic proteins including complex IV subunit 2,
and β-actin indicating that general protein degradation or autop-
hagy are not causing the decrease in GAC and that the decrease in
GAC protein levels is modulated by thiol modiﬁcation.
The effects of IBTP on GAC protein levels over time were then
studied. Cells were treated with either BTPP or IBTP (10 mM) for
various time points and GAC protein levels were monitored. BTPP
had no effect on GAC as seen in Fig. 8 while IBTP treatment de-
creased GAC protein levels to 36% of BTPP levels after 12h and to
12% of BTPP levels after 24h (Fig. 10A and B). When cells were
treated for 24 h and allowed to recover up to 48 h in drug free
media, GAC protein levels did not recover, but remained near 5% of
BTPP levels (Figs. 10A and B). To ensure that the decrease in GAC
protein abundance was not due to disruption of an epitope on GAC
after TPP adduct formation, the decrease in GAC was conﬁrmed
using a different antibody (Fig. S3). Overall, these results indicate
that GAC protein levels are decreased in response to mitochondrial
thiol modiﬁcation, and that this effect persists after removal of
IBTP.
We then sought to determine whether the decrease in GAC
protein corresponds temporally to the accumulation of TPP ad-
ducts. Cell lysates were probed for TPP-protein adducts by Wes-
tern blot analysis, and were signiﬁcantly increased over the time-
frame corresponding to the GAC protein decrease (Fig. 10C).
However, when cells were allowed to recover in drug-free med-
ium, TPP adducts decreased by nearly half, but remained as high as
42% of maximal up to 48 h after removal of IBTP. Interestingly,
some individual TPP-protein adduct bands were profoundly de-
creased, while others appeared stable (Fig. S4), open arrowheads
vs. closed arrowheads). As expected, protein adducts were not
observed in cells treated with the non-electrophilic analog BTPP
(Fig. S4). These results demonstrate that TPP adducts are formed
over a similar time frame as GAC protein depletion, and suggest
that the fates of TPP-adducts are protein-dependent, resulting in
TPP adduct clearance, changes in protein level, or persistence of
adducts on speciﬁc proteins.4. Discussion
In this study, we examined the functional effects of mi-
tochondrial thiol modiﬁcation through the use of a mitochondria-
targeted electrophile, IBTP, metabolism, and enzyme activity and
protein levels using both a breast cancer cell line (MB231) and an
immortalized nontumorigenic epithelial cell line (MCF-10A). Other
TPP-linked compounds including mitochondria-targeted ubiquinol
(MitoQ), and mitochondria-targeted α-tocopherol (MitoE) have
previously been shown to inhibit mitochondrial respiration, and
other studies including our own have indicated that TPPþ itself
can elicit effects on mitochondrial bioenergetics [27,34]. Length of
the TPPþ moiety has also been shown to a factor in the inhibition
of mitochondria metabolism. In fact, increasing the linker portion
of the targeting moiety to 8 carbons or higher was shown to
suppress mitochondrial bioenergetics and dysregulate mitochon-
drial calcium channel function. The effects of longer chain linker
regions could lead to a more pro-cytotoxic environment when
compared to shorter chain TPPþ-linked compounds such as IBTP,
which has a 4 carbon linker. The role of IBTP and other shorter
chain TPPþ compounds in calcium dysregulation have not been
elucidated to date [35–37], We showed that both BTPP and IBTP
elicited effects on bioenergetic parameters in both cell lines
(Figs. 1–2), but that IBTP, which is capable of thiol modiﬁcation,
was more potent than BTPP, which contains only the targeting
Fig. 7. Targeted metabolomic analysis. MB231 cells were treated with vehicle (EtOH), IBTP (10 mM), or BTPP (10 mM) for 24 h and Krebs cycle and related metabolite levels
were measured. The values are mean 7SEM, n¼5 samples *Po0.05 compared to vehicle. #Po0.05 compared to BTPP.
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modiﬁcation contributes to inhibition of mitochondrial respira-
tion. We determined that the decrease in bioenergetics was not
due to a decrease in overall mitochondrial content, since levels ofcitrate synthase protein were not changed after exposure to the
highest concentration of BTPP or IBTP (10 mM; data not shown).
The fact that non-mitochondrial respiration was signiﬁcantly de-
creased by IBTP is also of interest. Non-mitochondrial respiration
Fig. 8. Thiol Modiﬁcation of Aconitase Activity. MB231 cells were treated with IBTP
(5–10 mM) or BTPP (5–10 mM) for 24 h. Cells lysates were prepared and aconitase
activity was measured via in-gel activity assay. Values represent mean7SEM, n¼4
obtained from 2 independent experiments; *Po0.05 compared to vehicle.
#Po0.05 compared to BTPP.
Fig. 9. Glutaminase and other protein levels. MB231 cells were treated with vehicle
(EtOH), IBTP (10 mM), or BTPP (10 mM) for 24 h. Cell lysates were prepared and
proteins were visualized by Western blot analysis using a polyclonal anti-GAC/KGA
antibody, complex IV subunit 2 (CIV.2), or β-actin. The images within each protein
were taken from the same blot image and identically contrasted for representation.
Images are representative from two independent experiments.
Fig. 10. Time course of glutaminase protein levels. Panel A: MB231 cells were
treated with IBTP (10 mM) or BTPP (10 mM) for the indicated times (4–24 h), or were
treated for 24 h followed by removal of the treatment and recovery for 24 or 48 h.
Representative image of western blots for glutaminase (GAC and KGA) obtained
using a polyclonal anti-GAC/KGA antibody. Cytosolic aconitase (ACO1) was used as
a loading control. Panel B: Quantiﬁcation of GAC from Panel A. Values represent
mean7SEM, n¼9 obtained from three independent experiments; *Po0.05 com-
pared to 4hr BTPP treatment. Panel C: TPP adducts in IBTP-treated cell lysates were
visualized by Western blot analysis and quantiﬁed. Values represent percent of
adducts observed at 24 h. Values represent mean 7SEM of 9 samples obtained
from three independent experiments; *Po0.05 compared to 24 h IBTP treatment.
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cluding xanthine oxidase, cytochrome P450 and other forms of
oxidases [38,39]. Interestingly, xanthine synthesis requires ade-
nonucleotides, which we have shown to be decreased after IBTP
treatment, in order to generate the precursor inosine. Decreased
inosine in turn would lead to decreased hypoxanthine, which is a
substrate of xanthine oxidase. While other oxygen consuming
cytosolic pathways could be involved, this is an example of one
potential pathway which could explain the effect of mitochondrial
thiol modiﬁcation on non-mitochondrial respiration.
Interestingly, the metabolic phenograms of both cell lines show
that, at baseline, the MB231 cells are in a higher energetic state
than the non-tumorigenic MCF10A cells (Fig. 3A and B), and by
treating with increasing concentrations of IBTP a signiﬁcant de-
crease in both OCR and eventually ECAR leading to a more
quiescent state in MB231 cells is seen. However, in the MCF10A
cells, a signiﬁcant compensatory increase in ECAR occurs si-
multaneously with the decrease in OCR at all but the highest
concentration which appears to exceed the cells compensatory
mechanisms. The increase in ECAR could be a result of increased
glycolysis, and could represent the cell's attempt to maintain
homeostasis and adequate ATP levels. Due to the differential me-
tabolic effects of IBTP on tumorigenic and non-tumorigenic cells,
mitochondria-targeted thiol modiﬁcation could have signiﬁcanttherapeutic potential; however, additional studies are warranted
to investigate this possibility.
Adenonucleotide amounts increased over time, even after
normalization to protein amounts (Fig. 5A–D). Dolﬁ et al. showed
ATP levels per cell are not constant, but are proportional to cell
size [40]. Thus, we speculate that ATP levels increase due to
changes in cell size or volume over 6 days. Another key difference
observed in IBTP-treated cells which was not recapitulated in
BTPP-treated cells, was the induction of a more quiescent en-
ergetic state. This was supported by a decrease in the overall ATP:
ADP ratio, indicating a lower steady-state for cellular energy
supply and demand (Fig. 5E and S2) [41–43]. This increase in ATP:
ADP could also indicate a shift to a higher glycolytic state, a phe-
nomenon which has been previously reported [44] and is sup-
ported by our ECAR data (Fig. S1). Perhaps one of the most sur-
prising results in our study was that no appreciable cell death was
observed in IBTP-treated cells at the highest concentration of
compound tested (10 mM), despite the profound alterations in
bioenergetics and adenonucleotides (Fig. 6A). However, the de-
crease in bioenergetics and adenonucleotides may have con-
tributed to the decrease in cellular proliferation in MB231 cells,
since they exhibited a more quiescent energy state in response to
IBTP adduction in the metabolic phenograms (Fig. 6B). It is not
clear whether this shift toward a quiescent energy state is
M.R. Smith et al. / Redox Biology 8 (2016) 136–148 147equivalent to true cellular quiescence, or whether the cells are
slowly undergoing cell death. Although some cancer cells can re-
main quiescent for long periods of time, further studies are ne-
cessary to determine the nature of IBTP-induced quiescence and
how long it can persist in vivo.
The decreased energy status of IBTP-treated cells was accom-
panied by decreased glycolytic and Krebs cycle metabolites, sug-
gesting an upstream role for mitochondrial protein thiol mod-
iﬁcation in metabolite ﬂux leading to energy production (Fig. 7).
Interestingly, the fact that IBTP decreases glycolytic metabolites
was unexpected. While we cannot rule out the possibility that IBTP
forms a small of number of cytosolic adducts that could inhibit
glycolysis, the rate of adduct formation of iodo-compounds with
thiols is relatively slow compared with the rate of TPPþ-accu-
mulation within the mitochondria [45], which would not support
the concept of cytosolic protein adducts being a major factor. In
addition, glucose-6-phosphate and fructose-6-phosphate levels
were decreased by both BTPP and IBTP, suggesting that the effects
on glycolysis are not due to thiol modiﬁcation, but are more likely
due to the TPPþ moiety. Nevertheless, the effects of IBTP and BTPP
on glycolysis could be due to either direct interaction of the
compounds with cytosolic components, or indirect action of these
compounds on mitochondrial calcium channels or other processes.
The fact that ADP levels are decreased by both IBTP and BTPP
suggests that allosteric activation of glycolysis may be suppressed
by these compounds. Other possibilities include increased ﬂux
through the pentose-phosphate pathway which could shunt glu-
cose-6-phosphate from glycolysis in order to generate NADPH.
Changes to the Krebs cycle metabolites α-ketoglutarate, fuma-
rate, malate, and oxaloacetate were not observed with BTPP
treatment, indicating that the anti-anaplerotic effects are depen-
dent on mitochondrial thiol modiﬁcation. Previous studies by our
lab and others using isolated mitochondria in other cell types have
shown that IBTP forms adducts with several proteins involved in
the Krebs cycle [24,25,28,29]. In this study, we showed that aco-
nitase enzymatic activity and GAC protein levels were decreased
by IBTP (Figs. 8–10). These enzymes represent two important en-
try points for metabolic intermediates into the Krebs cycle, and
metabolites downstream of these enzymes were decreased in cells
exposed to IBTP. In addition, other metabolites were also de-
creased, presumably because intermediates were not available for
conversion, and/or because other Krebs cycle enzymes are in-
hibited by IBTP which have not previously been reported. Aconi-
tase has previously been shown to be a target of IBTP adduction,
but it is not yet knownwhether GAC is also adducted. In a study by
Campos et al., N-ethylmaleimide (NEM), a thiol-reactive reagent,
inhibited glutaminase activity. Further studies will be necessary to
determine whether there is a reactive cysteine near or within the
binding site of GAC which could be modiﬁed by IBTP [17]. The fact
that IBTP decreased GAC protein, without affecting the levels of
other proteins such as complex IV subunit 2, or β-actin, suggest
that GAC protein is selectively decreased by mitochondrial thiol
modiﬁcation (Figs. 9–10). It is important to note that GAC's role in
glutaminolysis is to convert glutamine to glutamate which can
then be converted to either α-ketoglutatate, or other amino acids
such as alanine, aspartate, or arginine which are required for
protein synthesis. With the loss of GAC, we would expect that the
amino acid substrates required protein would become limited and
this could potentially result in premature termination of protein
synthesis. The decrease in GAC protein is time-dependent and
unrecoverable up to 48 h after IBTP was removed (Figs. 10A and B;
S3). However, the exact mechanism by which mitochondrial thiol
modiﬁcation decreases GAC protein levels remains to be
elucidated.
In conclusion, we have demonstrated that mitochondrial thiol
modiﬁcation by IBTP induces a type of metabolic reprogrammingresulting in decreased mitochondrial bioenergetics, Krebs cycle
metabolites and adenine nucleotides in MB231 breast cancer cells.
The data presented in this study suggest mitochondrial thiol
modiﬁcation regulates metabolism and inhibits anaplerosis by
decreasing aconitase enzyme activity and GAC protein levels.
These effects on metabolism by mitochondrial thiol modiﬁcation
have important implications for the basic understanding of cancer
cell metabolism and the development of thiol speciﬁc cancer
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